PT - JOURNAL ARTICLE AU - The CRyPTIC Consortium AU - Philip W Fowler AU - Ivan Barilar AU - Simone Battaglia AU - Emanuele Borroni AU - Angela Pires Brandao AU - Alice Brankin AU - Andrea Maurizio Cabibbe AU - Joshua Carter AU - Daniela Maria Cirillo AU - Pauline Claxton AU - David A Clifton AU - Ted Cohen AU - Jorge Coronel AU - Derrick W Crook AU - Viola Dreyer AU - Sarah G Earle AU - Vincent Escuyer AU - Lucilaine Ferrazoli AU - George Fu Gao AU - Jennifer Gardy AU - Saheer Gharbia AU - Kelen Teixeira Ghisi AU - Arash Ghodousi AU - Ana Luíza Gibertoni Cruz AU - Louis Grandjean AU - Clara Grazian AU - Ramona Groenheit AU - Jennifer L Guthrie AU - Wencong He AU - Harald Hoffmann AU - Sarah J Hoosdally AU - Martin Hunt AU - Zamin Iqbal AU - Nazir Ahmed Ismail AU - Lisa Jarrett AU - Lavania Joseph AU - Ruwen Jou AU - Priti Kambli AU - Rukhsar Khot AU - Jeff Knaggs AU - Anastasia Koch AU - Donna Kohlerschmidt AU - Samaneh Kouchaki AU - Alexander S Lachapelle AU - Ajit Lalvani AU - Simon Grandjean Lapierre AU - Ian F Laurenson AU - Brice Letcher AU - Wan-Hsuan Lin AU - Chunfa Liu AU - Dongxin Liu AU - Kerri M Malone AU - Ayan Mandal AU - Mikael Mansjö AU - Daniela Matias AU - Graeme Meintjes AU - Flávia de Freitas Mendes AU - Matthias Merker AU - Marina Mihalic AU - James Millard AU - Paolo Miotto AU - Nerges Mistry AU - David Moore AU - Kimberlee A Musser AU - Dumisani Ngcamu AU - Hoang Ngoc Nhung AU - Stefan Niemann AU - Kayzad Soli Nilgiriwala AU - Camus Nimmo AU - Nana Okozi AU - Rosangela Siqueira Oliveira AU - Shaheed Vally Omar AU - Nicholas Paton AU - Timothy EA Peto AU - Juliana Maira Watanabe Pinhata AU - Sara Plesnik AU - Zully M Puyen AU - Marie Sylvianne Rabodoarivelo AU - Niaina Rakotosamimanana AU - Paola MV Rancoita AU - Priti Rathod AU - Esther Robinson AU - Gillian Rodger AU - Camilla Rodrigues AU - Timothy C Rodwell AU - Aysha Roohi AU - David Santos-Lazaro AU - Sanchi Shah AU - Thomas Andreas Kohl AU - Grace Smith AU - Walter Solano AU - Andrea Spitaleri AU - Philip Supply AU - Utkarsha Surve AU - Sabira Tahseen AU - Nguyen Thuy Thuong Thuong AU - Guy Thwaites AU - Katharina Todt AU - Alberto Trovato AU - Christian Utpatel AU - Annelies Van Rie AU - Srinivasan Vijay AU - Timothy M Walker AU - A Sarah Walker AU - Robin Warren AU - Jim Werngren AU - Maria Wijkander AU - Robert J Wilkinson AU - Daniel J Wilson AU - Penelope Wintringer AU - Yu-Xin Xiao AU - Yang Yang AU - Zhao Yanlin AU - Shen-Yuan Yao AU - Baoli Zhu TI - Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of <em>M. tuberculosis</em> AID - 10.1101/2021.02.24.21252386 DP - 2022 Jan 01 TA - medRxiv PG - 2021.02.24.21252386 4099 - http://medrxiv.org/content/early/2022/02/03/2021.02.24.21252386.short 4100 - http://medrxiv.org/content/early/2022/02/03/2021.02.24.21252386.full AB - Drug susceptibility testing of M. tuberculosis is rooted in a binary susceptible/resistant paradigm.Whilst there are considerable advantages in measuring the minimum inhibitory concentrations (MICs) of a panel of drugs for an isolate it is n ecessary to measure the epidemiological cutoff values (ECOFF/ECVs) to permit comparison with qualitative data. Here we present ECOFF/ECVs for 13 anti-TB compounds, including bedaquiline and delamanid, derived from 20,637 clinical isolates collected by 14 laboratories based in 11 countries on five continents. Each isolate was incubated for 14 days on a dry 96-well broth microdilution plate and then read. Resistance to most of the drugs due to prior exposure is expected and the MIC distributions for many of the compounds are complex and therefore a phenotypically wild-type population could not be defined. Since a majority of samples also underwent genetic sequencing, we defined a genotypically wild-type population and measured the MIC of the 99th percentile by direct measurement and via fitting a Gaussian using interval regression.The proposed ECOFF/ECV values were then validated by comparing to the MIC distributions of high-confidence genetic variants that confer resistance and to qualitative drug susceptibility tests obtained via Mycobacterial Growth Indicator Tube and the Microscopic-Observation Drug-Susceptibility assay.These ECOFF/ECV values will inform and encourage the more widespread adoption of broth microdilution – this is a cheap culture-based method that tests the susceptibility of 12-14 antibiotics on a single 96-well plate and so could help personalise the treatment of tuberculosis.Competing Interest StatementE.R. is employed by Public Health England and holds an honorary contract with Imperial College London. I.F.L. is Director of the Scottish Mycobacteria Reference Laboratory. S.N. receives funding from German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG)tion EXC 2167. P.S. is a consultant at Genoscreen. T.R. is funded by NIH and DoD and receives salary support from the non-profit organization FIND. T.R. is a co-founder, board member and shareholder of Verus Diagnostics Inc, a company that was founded with the intent of developing diagnostic assays. Verus Diagnostics was not involved in any way with data collection, analysis or publication of the results. T.R. has not received any financial support from Verus Diagnostics. UCSD Conflict of Interest office has reviewed and approved T.R.'s role in Verus Diagnostics Inc. T.R. is a co-inventor of a provisional patent for a TB diagnostic assay (provisional patent #: 63/048.989). T.R. is a co-inventor on a patent associated with the processing of TB sequencing data (European Patent Application No. 14840432.0 &amp; USSN 14/912,918). T.R. has agreed to "donate all present and future interest in and rights to royalties from this patent" to UCSD to ensure that he does not receive any financial benefits from this patent. S.S. is working and holding ESOPs at HaystackAnalytics Pvt. Ltd. (Product: Using whole genome sequencing for drug susceptibility testing for Mycobacterium tuberculosis). G.F.G. is listed as an inventor on patent applications for RBD-dimer-based CoV vaccines. The patents for RBD-dimers as protein subunit vaccines for SARS-CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.Funding StatementThis work was supported by Wellcome Trust/Newton Fund-MRC Collaborative Award (200205/Z/15/Z); and Bill &amp; Melinda Gates Foundation Trust (OPP1133541). Oxford CRyPTIC consortium members are funded/supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health, and the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, a partnership between Public Health England and the University of Oxford, the views expressed are those of the authors and not necessarily those of the NIHR, Public Health England or the Department of Health and Social Care. J.M. is supported by the Wellcome Trust (203919/Z/16/Z). Z.Y. is supported by the National Science and Technology Major Project, China Grant No. 2018ZX10103001. K.M.M. is supported by EMBL's EIPOD3 programme funded by the European Union's Horizon 2020 research and innovation programme under Marie Skiodowska Curie Actions. T.C.R. is funded in part by funding from Unitaid Grant No. 2019-32-FIND MDR. R.S.O. is supported by FAPESP Grant No. 17/16082-7. L.F. received financial support from FAPESP Grant No. 2012/51756-5. B.Z. is supported by the National Natural Science Foundation of China (81991534) and the Beijing Municipal Science &amp; Technology Commission (Z201100005520041). N.T.T.T. is supported by the Wellcome Trust International Intermediate Fellowship (206724/Z/17/Z). G.T. is funded by the Wellcome Trust. R.W. is supported by the South African Medical Research Council. J.C. is supported by the Rhodes Trust and Stanford Medical Scientist Training Program (T32 GM007365). A.L. is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Respiratory Infections at Imperial College London. S.G.L. is supported by the Fonds de Recherche en Sante du Quebec. C.N. is funded by Wellcome Trust Grant No. 203583/Z/16/Z. A.V.R. is supported by Research Foundation Flanders (FWO) under Grant No. G0F8316N (FWO Odysseus). G.M. was supported by the Wellcome Trust (098316, 214321/Z/18/Z, and 203135/Z/16/Z), and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No. 64787). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone. L.G. was supported by the Wellcome Trust (201470/Z/16/Z), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number 1R01AI146338, the GOSH Charity (VC0921) and the GOSH/ICH Biomedical Research Centre (www.nihr.ac.uk). A.B. is funded by the NDM Prize Studentship from the Oxford Medical Research Council Doctoral Training Partnership and the Nuffield Department of Clinical Medicine. D.J.W. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant No. 101237/Z/13/B) and by the Robertson Foundation. A.S.W. is an NIHR Senior Investigator. T.M.W. is a Wellcome Trust Clinical Career Development Fellow (214560/Z/18/Z). A.S.L. is supported by the Rhodes Trust. R.J.W. receives funding from the Francis Crick Institute which is supported by Wellcome Trust, (FC0010218), UKRI (FC0010218), and CRUK (FC0010218). T.C. has received grant funding and salary support from US NIH, CDC, USAID and Bill and Melinda Gates Foundation. The computational aspects of this research were supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford BRC. Parts of the work were funded by the German Center of Infection Research (DZIF). The Scottish Mycobacteria Reference Laboratory is funded through National Services Scotland. The Wadsworth Center contributions were supported in part by Cooperative Agreement No. U60OE000103 funded by the Centers for Disease Control and Prevention through the Association of Public Health Laboratories and NIH/NIAID grant AI-117312. Additional support for sequencing and analysis was contributed by the Wadsworth Center Applied Genomic Technologies Core Facility and the Wadsworth Center Bioinformatics Core. SYNLAB Holding Germany GmbH for its direct and indirect support of research activities in the Institute of Microbiology and Laboratory Medicine Gauting. N.R. thanks the Programme National de Lutte contre la Tuberculose de Madagascar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the CRyPTIC study was obtained by Taiwan Centers for Disease Control IRB No. 106209, University of KwaZulu Natal Biomedical Research Ethics Committee (UKZN BREC) (reference BE022/13), University of Liverpool Central University Research Ethics Committees (reference 2286), Institutional Research Ethics Committee (IREC) of The Foundation for Medical Research, Mumbai (Ref nos. FMR/IEC/TB/01a/2015 and FMR/IEC/TB/01b/2015), Institutional Review Board of P.D. Hinduja Hospital and Medical Research Centre, Mumbai (Ref no. 915-15- CR [MRC]), scientific committee of the Adolfo Lutz Institute (CTC-IAL 47-J / 2017) and in the Ethics Committee (CAAE: 81452517.1.0000.0059) and Ethics Committee review by Universidad Peruana Cayetano Heredia (Lima, Peru) and LSHTM (London, UK). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe numerical data used to plot Figures 2 and 3 from which the ECOFF/ECVs are derived is included in a Supplemental CSV file. In addition, one can reproduce nearly all the tables and figures, along with the Supplemental Data, in a browser window (i.e. no installation required) using Python code we have made publicly available here: https://github.com/fowler-lab/cryptic-ecoffs https://github.com/fowler-lab/cryptic-ecoffs